Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan; Graduate Institute of Medical Sciences, Taipei Medical University, Taiwan; General Education Center, Tatung University, Taipei, Taiwan.
Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Medical Center, Taoyuan, Taiwan; Chang Gung University Medical College, Taoyuan, Taiwan.
Gynecol Oncol. 2015 Jun;137(3):468-73. doi: 10.1016/j.ygyno.2015.03.015. Epub 2015 Mar 20.
To evaluate the role of surgery, radiation therapy and chemotherapy in the management of small cell carcinoma of the uterine cervix (SCCC) through a retrospective study of Taiwanese Gynecologic Oncology Group.
We reviewed the medical records and histological files of 144 patients with FIGO stages IA-IIB SCCC treated in 11 main hospitals in Taiwan from 1987 to 2009.
There were 110 patients receiving primary surgery and 34 primary radiation therapy. Most patients in each group also received chemotherapy as part of primary treatment. A lower loco-regional failure rate was observed in patients who received primary radiation therapy than in those who had primary surgery (6% vs. 27%; P=0.009). The 5-year overall survival (OS) was 89% for 13 surgically treated patients with cervical tumor ≤2cm and no lymphovascular space involvement (LVSI) in whom recurrence was noted in 2 of 4 patients without receiving adjuvant chemotherapy and none in the 9 patients who had chemotherapy. Excluding these 13 patients, primary radiation therapy with at least 5cycles of platinum-based chemotherapy (n=14, including 12 stages IB2-IIB) resulted in a 5-year OS of 78%, better than that of 46% by primary surgery (n=97, including 40 stages IB2-IIB) (P=0.046).
None of the 9 patients with cervical tumor ≤2cm and no LVSI showed disease recurrence after primary surgery and adjuvant chemotherapy. For most patients with stages I-II, primary radiation therapy with aggressive chemotherapy was associated with better survival than surgery.
通过对台湾妇科肿瘤学组的回顾性研究,评估手术、放疗和化疗在子宫颈小细胞癌(SCCC)治疗中的作用。
我们回顾了 1987 年至 2009 年台湾 11 家主要医院收治的 144 例国际妇产科联盟(FIGO)分期为 IA-IIB 的 SCCC 患者的病历和组织学档案。
110 例患者接受了根治性手术,34 例患者接受了根治性放疗。每组大多数患者也接受了化疗作为主要治疗的一部分。接受根治性放疗的患者局部区域复发率低于接受根治性手术的患者(6%对 27%;P=0.009)。在未接受辅助化疗的 4 例无复发患者和接受化疗的 9 例患者中,手术治疗的 13 例宫颈肿瘤≤2cm 且无淋巴血管间隙浸润(LVSI)的患者 5 年总生存率(OS)为 89%。排除这 13 例患者后,至少接受 5 个周期铂类为基础的化疗的根治性放疗(n=14,包括 12 例 IB2-IIB 期),5 年 OS 为 78%,优于根治性手术(n=97,包括 40 例 IB2-IIB 期)(P=0.046)。
无 LVSI 的宫颈肿瘤≤2cm 的 9 例患者在根治性手术和辅助化疗后均无疾病复发。对于大多数 I-II 期患者,积极化疗的根治性放疗与手术相比,生存获益更好。